NATTOPHARMA ASA Daniel H. Rosenbaum has been appointed as Chief Operating Officer of NattoPharma USA, Inc. Rosenbaum will work from the NattoPharma US office in New Jersey, and report to CEO Hogne Vik, located in Norway.
"The employment of Daniel H. Rosenbaum reflects a swift in our company and points to the opportunity for a significant growth of the science-backed vitamin K2 market for MenaQ7" says Frode M. Bohan, Chairman of NattoPharma ASA, Høvik, Norway.
"Rosenbaum has a strong nettwork within the omega-3- and dietary supplement industry. This, in combination with the increasing business potential for MenaQ7 in US ,NattoPharma has great expectations for the future".
Prior to joining NattoPharma, Rosenbaum served as General Manager of Nutraceuticals of FMC Health & Nutrition, a division of the Philadelphia, PA-based FMC Corporation, an $8.5 billion market cap NYSE-listed chemical company, where he worked in various leadership capacities starting in 1995. Most recently at FMC health & Nutrition, Rosenbaum led the integration of the $345-million acquisition of a premium Omega-3 producer, with operations in Norway and UK.
"Rosenbaum has achieved proven successes in business turnarounds, international assignments, acquisitions and startups" says Hogne Vik, CEO in NattoPharma. "His background has shown that he builds motivated, high-performance organizations, which makes him perfectly suited for our needs and for the fulfillment of both our short-term and long-term goals."
Since launching North American operations 2013 under Eric Anderson, global vice president of sales and marketing, MenaQ7 has been introduced in a variety of dietary supplements, as a medical food, and has been added to the shelves of both CVS and Walgreens, the leading U.S. pharmacy chains.
Rosenbaum's role will be to help drive and realize the next commercial phase of NattoPharma and its signature ingredient, MenaQ7, and to add strategic capabilities to enable further business growth.
# # #
About MenaQ7®
MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7(MK-7). MenaQ7 is the purest and best documented natural vitamin K2 with guaranteed actives and stability, clinical substantiation and several granted patents on cardiovascular health.
About NattoPharma
As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator and leader of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in a research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.
For more information, please contact:
Hogne Vik,
CEO (+47-97535326
Hogne.vik@nattopharma.com
or
Kate Quackenbush
Director of Communications
(609) 643-0748
kate.quackenbush@nattopharma.com
Tags:
|
distributed by
|
